Role of catecholamines and serotonin receptor subtypes in nefopam-induced antinociception

Pharmacological Research

Volumn 54, Issue 3, 2006, Pages 195-202

  Girard, Philippe ^a   Coppé, Marie Claude ^a   Verniers, Danielle ^a   Pansart, Yannick ^a   Gillardin, Jean Marie ^a  

^a Service de Pharmacologie   (France)

Author keywords

Catecholamines; Formalin; Nefopam; Serotonergic; Writhing

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 2 (DIETHYLAMINO)ETHYL ESTER; 8 [4 (5 AMINO 2,4 DIMETHOXYBENZOYL)BUTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETIC ACID; CATECHOLAMINE DERIVATIVE; FORMALDEHYDE; KETANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEFOPAM; R 96544; SEROTONIN 2C ANTAGONIST; SEROTONIN RECEPTOR; SULPIRIDE; TROPISETRON; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; WRITHING TEST;

ADRENERGIC ALPHA-ANTAGONISTS; ANALGESICS, NON-NARCOTIC; ANIMALS; BIOGENIC MONOAMINES; CATECHOLAMINES; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED ICR; NEFOPAM; NOCICEPTORS; PRAZOSIN; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D1; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 33746362623     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.04.008     Document Type: Article

References (56)

1. Du Manoir B., Aubrun F., Langlois M., Le Guern M.E., Alquier C., Chauvin M., et al. Randomized prospective study of the analgesic effect of nefopam after orthopaedic surgery. Br J Anaesth 91 (2003) 836-841
2. Heel R.C., Brogden R.N., Pakes G.E., Speight T.M., and Avery G.S. Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 19 (1980) 249-267
3. Kapfer B., Alfonsi P., Guignard B., Sessler D.I., and Chauvin M. Nefopam and ketamine comparably enhance postoperative analgesia. Anesth Analg 100 (2005) 169-174
4. Mimoz O., Incagnoli P., Josse C., Gillon M.C., Kuhlman L., Mirand A., et al. Analgesic efficacy and safety of nefopam vs. propacetamol following hepatic resection. Anaesthesia 56 (2001) 520-525
5. Buritova J., and Besson J.M. Effects of nefopam on the spinal nociceptive processes: a c-Fos protein study in the rat. Eur J Pharmacol 441 (2002) 67-74
6. Conway A.C., and Mitchell C.L. Analgesic studies with nefopam hydrochloride. Arch Int Pharmacodyn Ther 226 (1997) 156-171
7. Fasmer O.B., Berge O.G., Jorgensen H.A., and Hole K. Antinociceptive effects of (+/-)-, (+)- and (-)-nefopam in mice. J Pharm Pharmacol 39 (1987) 508-511
8. Girard P., Pansart Y., Coppe M.C., and Gillardin J.M. Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat. Pharmacol Res 44 (2001) 541-545
9. Piercey M.F., and Schroeder L.A. Spinal and supraspinal sites for morphine and nefopam analgesia in the mouse. Eur J Pharmacol 74 (1981) 135-140
10. Biella G.E., Groppetti A., Novelli A., Fernandez-Sanchez M.T., Manfredi B., and Sotgiu M.L. Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine. J Neurotrauma 20 (2003) 593-601
11. Fernandez-Sanchez M.T., Diaz-Trelles R., Groppetti A., Manfredi B., Brini A.T., Biella G., et al. Novel effect of nefopam preventing cGMP increase, oxygen radical formation and neuronal death induced by veratridine. Neuropharmacology 41 (2001) 935-942
12. Verleye M., Andre N., Heulard I., and Gillardin J.M. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 1013 (2004) 249-255
13. Fuller R.W., and Snoddy H.D. Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice. Neuropharmacology 32 (1993) 995-999
14. Rosland J.H., and Hole K. The effect of nefopam and its enantiomers on the uptake of 5-hydroxytryptamine, noradrenaline and dopamine in crude rat brain synaptosomal preparations. J Pharm Pharmacol 42 (1990) 437-438
15. Tresnak-Rustad N.J., and Wood M.E. In vitro biochemical effects of nefopam hydrochloride, a new analgesic agent. Biochem Pharmacol 30 (1981) 2847-2850
16. Bardin L., Bardin M., Lavarenne J., and Eschalier A. Effect of intrathecal serotonin on nociception in rats: influence of the pain test used. Exp Brain Res 113 (1997) 81-87
17. Frussa-Filho R., Rocha J.B., Conceicao I.M., Mello C.F., and Pereira M.E. Effects of dopaminergic agents on visceral pain measured by the mouse writhing test. Arch Int Pharmacodyn Ther 331 (1996) 74-93
18. Magnusson J.E., and Fisher K. The involvement of dopamine in nociception: the role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res 855 (2000) 260-266
19. Millan M.J. The induction of pain: an integrative review. Prog Neurobiol 57 (1999) 1-164
20. Raja S.N. Role of the sympathetic nervous system in acute pain and inflammation. Ann Med 27 (1995) 241-246
21. Tasker R.A., Connell B.J., and Yole M.J. Systemic injections of alpha-1 adrenergic agonists produce antinociception in the formalin test. Pain 49 (1992) 383-391
22. 2-adrenoceptors in the nucleus raphe magnus in opioid analgesia and opioid abstinence-induced hyperalgesia. J Neuroscience 23 (2003) 7950-7957
23. Sierralta F., Naquira D., Pinardi G., and Miranda H.F. alpha-adrenoceptor and opioid receptor modulation of clonidine-induced antinociception. Br J Pharmacol 119 (1996) 551-554
24. Flores J.A., El Banoua F., Galan-Rodriguez B., and Fernandez-Espejo E. Opiate anti-nociception is attenuated following lesion of large dopamine neurons of the periaqueductal grey: critical role for D1 (not D2) dopamine receptors. Pain 110 (2004) 205-214
25. Millan M.J., Seguin L., Honore P., Girardon S., and Bervoets K. Pro- and antinociceptive actions of serotonin (5-HT)1A agonists and antagonists in rodents: relationship to algesiometric paradigm. Behav Brain Res 73 (1996) 69-77
26. Shannon H.E., and Lutz E.A. Yohimbine produces antinociception in the formalin test in rats: involvement of serotonin(1A) receptors. Psychopharmacology (Berlin) 149 (2000) 93-97
27. Ghelardini C., Galeotti N., Nicolodi M., Donaldson S., Sicuteri F., and Bartolini A. Involvement of central cholinergic system in antinociception induced by sumatriptan in mouse. Int J Clin Pharmacol Res 17 (1997) 105-109
28. Hain H.S., Belknap J.K., and Mogil J.S. Pharmacogenetic evidence for the involvement of 5-hydroxytryptamine (serotonin)-1B receptors in the mediation of morphine antinociceptive sensitivity. J Pharmacol Exp Ther 291 (1999) 444-449
29. Sasaki M., Ishizaki K., Obata H., and Goto F. Effects of 5-HT2 and 5-HT3 receptors on the modulation of nociceptive transmission in rat spinal cord according to the formalin test. Eur J Pharmacol 424 (2001) 45-52
30. Alhaider A.A. Antinociceptive effect of ketanserin in mice: involvement of supraspinal 5-HT2 receptors in nociceptive transmission. Brain Res 543 (1991) 335-340
31. Chojnacka-Wojcik E., Klodzinska A., and Deren-Wesolek A. Involvement of 5-HT2C receptors in the m-CPP-induced antinociception in mice. Pol J Pharmacol 46 (1994) 423-428
32. Moser P.C. The effect of 5-HT3 receptor antagonists on the writhing response in mice. Gen Pharmacol 26 (1995) 1301-1306
33. Arcioni R., della Rocca M., Romano S., Romano R., Pietropaoli P., and Gasparetto A. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg 94 (2002) 1553-1557
34. Ghelardini C., Galeotti N., Casamenti F., Malmberg-Aiello P., Pepeu G., Gualtieri F., et al. Central cholinergic antinociception induced by 5HT4 agonists: BIMU 1 and BIMU 8. Life Sci 58 (1996) 2297-2309
35. Espejo E.F., and Gil E. Antagonism of peripheral 5-HT4 receptors reduces visceral and cutaneous pain in mice, and induces visceral analgesia after simultaneous inactivation of 5-HT3 receptors. Brain Res 788 (1998) 20-24
36. Ohkubo Y., Nomura K., and Yamaguchi I. Involvement of dopamine in the mechanism of action of FR64822, a novel non-opioid antinociceptive compound. Eur J Pharmacol 204 (1991) 121-125
37. Vonvoigtlander P.F., Lewis R.A., Neff G.L., and Triezenberg H.J. Involvement of biogenic amines with the mechanisms of novel analgesics. Prog Neuropsychopharmacol Biol Psychiatry 7 (1983) 651-656
38. Esposito E., Romandini S., Merlo-Pich E., Mennini T., and Samanin R. Evidence of the involvement of dopamine in the analgesic effect of nefopam. Eur J Pharmacol 128 (1986) 157-164
39. Hunskaar S., Fasmer O.B., Broch O.J., and Hole K. Involvement of central serotonergic pathways in nefopam-induced antinociception. Eur J Pharmacol 138 (1987) 77-82
40. Malmberg-Aiello P., Lamberti C., Ghelardini C., Giotti A., and Bartolini A. Role of histamine in rodent antinociception. Br J Pharmacol 111 (1994) 1269-1279
41. Dubuisson D., and Denis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4 (1977) 161-174
42. Hunskaar S., and Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 30 (1987) 103-114
43. Litchfield J.T., and Wilcoxon F. A simple method for evaluating dose-effect experiments. J Pharmacol Exp Ther 96 (1949) 99-113
44. Gray A.M., Nevinson M.J., and Sewell R.D. The involvement of opioidergic and noradrenergic mechanisms in nefopam antinociception. Eur J Pharmacol 365 (1999) 149-157
45. Pini L.A., Sandrini M., and Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol 308 (1996) 31-40
46. Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281 (1995) 81-88
47. Ogawa T., Sugidachi A., Tanaka N., Fujimoto K., and Asai F. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444. Eur J Pharmacol 457 (2002) 107-114
48. Richardson B.P., Engel G., Donatsch P., and Stadler P.A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316 (1985) 126-131
49. Buchheit K.H., Gamse R., and Pfannkuche H.J. SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum. Naunyn Schmiedebergs Arch Pharmacol 345 (1992) 387-393
50. Alloui A., Chassaing C., Schmidt J., Ardid D., Dubray C., Cloarec A., et al. Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats. Eur J Pharmacol 443 (2002) 71-77
51. Bonhaus D.W., Weinhardt K.K., Taylor M., DeSouza A., McNeeley P.M., Szczepanski K., et al. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 36 (1997) 621-629
52. Hwang A.S., and Wilcox G.L. Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain 28 (1987) 343-355
53. Gatch M.B., Negus S.S., and Mello N.K. Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys. Psychopharmacology (Berlin) 135 (1998) 99-106
54. Korzeniewska-Rybicka I., and Plaznik A. Supraspinally mediated analgesic effect of antidepressant drugs. Pol J Pharmacol 52 (2000) 93-99
55. Pedersen L.H., Nielsen A.N., and Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology (Berlin) 182 (2005) 551-561
56. Loomis C.W., Jhamandas K., Milne B., and Cervenko F. Monoamine and opioid interactions in spinal analgesia and tolerance. Pharmacol Biochem Behav 26 (1987) 445-451